Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.23.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Apr. 30, 2023
Apr. 30, 2022
Apr. 30, 2023
Apr. 30, 2022
Oct. 31, 2022
Segment Reporting Information [Line Items]          
Total $ (2,307) $ (3,588) $ (4,661) $ (7,467)  
Total operating costs and expenses 2,770 3,589 5,326 7,469  
Less non-cash stock-based compensation (1,227) (1,745) (2,290) (4,099)  
Total 1,543 1,844 3,036 3,370  
Total 27,599   27,599   $ 30,412
Cart Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Total (997) (1,399) (1,908) (3,010)  
Total 620 733 1,218 1,402  
Total 11,682   11,682   16,921
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Total (913) (1,423) (1,871) (2,780)  
Total 523 716 1,111 1,196  
Total 10,638   10,638   9,442
Anti Viral Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Total (416) (757) (898) (1,661)  
Total 212 388 517 760  
Total 4,953   4,953   3,811
Other [Member]          
Segment Reporting Information [Line Items]          
Total 19 (9) 16 (16)  
Total 188 $ 7 190 $ 12  
Total $ 326   $ 326   $ 238